美国VaxInnate
VaxInnate公司是一家私人持有的生物技术公司，开发新颖，专有疫苗为大流行病和季节性流感。该公司的突破疫苗是基于其Toll样受体（ TLR为）的技术平台，大大提高了疫苗的免疫原性和有效性。利用TLR为技术，疫苗可产生的简单，低成本，高可扩展性重组DNA技术，避免许多挑战和隐患的鸡蛋或细胞培养流感疫苗的生产。 VaxInnate的技术有可能显着提高成本效益，制造能力和效力的流感疫苗-面临的关键问题的临床和公共健康的社区。

美国生物制药公司VaxInnate总裁艾伦·肖在接受新华社记者采访时表示，针对这种新型病毒(猪流感病毒)的疫苗样品有望在4周内研制成功。

VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company's breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy. Using the TLR technology, vaccines can be produced by simple, low-cost, highly-scalable recombinant DNA techniques, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate's technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines - key issues facing the clinical and public health communities.

VaxInnate has a BSL2+ laboratory operational within the Cranbury site, and also has access to BSL-2 vivarium space through a collaborative research agreement with Yale University . VaxInnate also has a collaborative arrangement with an academic institution for access to high level biocontainment facilities (BSL-3 and -4). Since avian influenza requires BSL-3 or -4 facilities, depending on the strain in question, this access enables the VaxInnate to conduct live virus challenges in animal models.

VaxInnate was founded by Ruslan Medzhitov and Richard Flavell, both of Yale University and Howard Hughes Medical Institute and leaders in the field of innate immunity. The company started in 2002 with Michael Sherman serving as Chief Executive Officer and a research team in New Haven , CT. In 2004, the company expanded and established a development team and corporate headquarters in Cranbury , NJ . The company currently has approximately 58 employees including 18 with doctoral degrees.

Currently, VaxInnate occupies approximately 30,000 square feet of laboratory and office space in Cranbury , NJ , and New Haven , CT. This includes molecular and cell biology labs, cell culture facilities, a protein pilot plant and analytical laboratory space.

VaxInnate has raised more than $64 million to date and is backed by well-known venture capital firms, including HealthCare Ventures, Oxford Bioscience Partners LLC, MedImmune Ventures, Inc., CHL Medical Partners, New Leaf Venture Partners, and Canaan Partners.